Anavex Life Sciences Corp. (AVXL)

NASDAQ: AVXL · IEX Real-Time Price · USD
10.80
-0.07 (-0.64%)
Feb 1, 2023, 11:07 AM EST - Market open
-0.64%
Market Cap 845.11M
Revenue (ttm) n/a
Net Income (ttm) -47.98M
Shares Out 77.96M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 239,800
Open 10.89
Previous Close 10.87
Day's Range 10.57 - 10.98
52-Week Range 7.13 - 15.24
Beta 0.74
Analysts Buy
Price Target 43.35 (+301.39%)
Earnings Date Feb 8, 2023

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multip... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Christopher Missling
Employees 38
Stock Exchange NASDAQ
Ticker Symbol AVXL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AVXL stock is "Buy." The 12-month stock price forecast is $43.35, which is an increase of 301.39% from the latest price.

Price Target
$43.35
(301.39% upside)
Analyst Consensus: Buy
Stock Forecasts

News

6 Favorite Biotech Bets For 2023

Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's...

Other symbols: AXNXMNKDNBIXSAVAVRTX
3 weeks ago - Forbes

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer's Trial

NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

1 month ago - GlobeNewsWire

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

1 month ago - GlobeNewsWire

Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.

2 months ago - Zacks Investment Research

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ET Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ET

2 months ago - GlobeNewsWire

Why Is Anavex Life Sciences (AVXL) Stock Up 30% Today?

Anavex Life Sciences (NASDAQ: AVXL) stock is rocketing higher on Friday following positive results from a clinical trial. The results come from its Phase 2b/3 clinical trial of ANAVEX®2-73.

2 months ago - InvestorPlace

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer's Disease

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

2 months ago - GlobeNewsWire

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time

2 months ago - GlobeNewsWire

Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ET Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ET

2 months ago - GlobeNewsWire

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

3 months ago - GlobeNewsWire

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer's Disease at the Upcoming Clinical Trials on Alzheimer's Disease (CTAD) Congress 2022

NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

3 months ago - GlobeNewsWire

Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy

Issuance of Anavex's Newest U.S. Patent Will Expand Anavex's Intellectual Property Portfolio Surrounding ANAVEX®2-73 Issuance of Anavex's Newest U.S. Patent Will Expand Anavex's Intellectual Property ...

4 months ago - GlobeNewsWire

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease

Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1

5 months ago - GlobeNewsWire

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results

Company to host a webcast today at 4:30 p.m. Eastern Time

6 months ago - GlobeNewsWire

Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022

Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET

6 months ago - GlobeNewsWire

Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer's Disease at AAIC 2022

ANAVEX®3-71 effect is supported by biomarkers: Decrease of extracellular A (Abeta) deposition and reduced pathological inflammatory glial cell recruitment towards hippocampal neurons (p ≤ 0.01) ANAVEX...

6 months ago - GlobeNewsWire

Anavex Announces First Entire Clinical Alzheimer's Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer's and Parkinson's disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p

6 months ago - GlobeNewsWire

Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 179%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab...

7 months ago - Zacks Investment Research

Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 238%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab...

7 months ago - Zacks Investment Research

How Much Upside is Left in Anavex Life Sciences (AVXL)? Wall Street Analysts Think 286%

The average of price targets set by Wall Street analysts indicates a potential upside of 286.4% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab...

8 months ago - Zacks Investment Research

Anavex's Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome

Publication Demonstrates the Feasibility to Use Blood Biomarkers to Monitor Response to ANAVEX®2-73 (blarcamesine) in Clinical Trials of Fragile X Syndrome (Major Cause of Autism) Publication Demonstr...

8 months ago - GlobeNewsWire

Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable...

9 months ago - Zacks Investment Research

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

9 months ago - GlobeNewsWire

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

Company to host a webcast today at 4:30 p.m. Eastern Time

9 months ago - GlobeNewsWire

(AVXL) News: Did You Lose Money on Anavex Life Sciences Corp. Investment? Contact Johnson Fistel Regarding Class Action Investigation

San Diego, California--(Newsfile Corp. - May 6, 2022) - Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal securities laws by Anavex Life Sciences Corp. (...

9 months ago - Newsfile Corp